Literature DB >> 23075507

Inhibition of antibody production in vivo by pre-stimulation of Toll-like receptor 4 before antigen priming is caused by defective B-cell priming and not impairment in antigen presentation.

Nurlaely Mida Rachmawati1, Kenji Fukudome, Naoko Tsuneyoshi, Uleng Bahrun, Hiroki Tsukamoto, Tsutomu Yanagibashi, Yoshinori Nagai, Kiyoshi Takatsu, Shoichiro Ohta, Masao Kimoto.   

Abstract

Stimulation of Toll-like receptor 4 (TLR4) induces not only innate but also adaptive immune responses, and has been suggested to exert adjuvant effects. Additional to such positive effects, pre-stimulation of TLR4 induces endotoxin tolerance where animals are unresponsive to subsequent lethal challenges with lipopolysaccharide (LPS). We examined the effects of pre-stimulation of TLR4 using an agonistic anti-TLR4 mAb (UT12) on antibody production in vivo. Pre-injection of UT12 prior to both primary and secondary immunization completely inhibited antigen-specific antibody responses. Cellular analysis revealed that the inhibition was not due to impairment of T-cell activation. Accordingly, T-helper activities in UT12 pre-injected mice were not impaired. In contrast, B-cell priming was defective in UT12 pre-injected mice. The observation that the expression of activation markers such as CD69 and CD86 on B cells was blocked by UT12 pre-injection supports this. Interestingly, UT12 pre-injection only showed inhibitory effects at the primary and not the secondary immunization. These results provide important information concerning the regulatory mechanisms of antibody production, especially in endotoxin-tolerant states.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23075507     DOI: 10.1093/intimm/dxs096

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  5 in total

1.  Irradiated tumor cells of lipopolysaccharide stimulation elicit an enhanced anti-tumor immunity.

Authors:  Yuli Li; Guobo Shen; Wen Nie; Zhimian Li; Yaxiong Sang; Binglan Zhang; Yuquan Wei
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-14       Impact factor: 4.553

2.  An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy.

Authors:  Hiroki Tsukamoto; Kanae Kubota; Ayumi Shichiku; Masamitsu Maekawa; Nariyasu Mano; Hideo Yagita; Shoichiro Ohta; Yoshihisa Tomioka
Journal:  Immunology       Date:  2019-10       Impact factor: 7.397

3.  Toll-Like Receptor 4 Agonistic Antibody Promotes Host Defense against Chronic Pseudomonas aeruginosa Lung Infection in Mice.

Authors:  Shigeki Nakamura; Naoki Iwanaga; Masafumi Seki; Kenji Fukudome; Kazuhiro Oshima; Taiga Miyazaki; Koichi Izumikawa; Katsunori Yanagihara; Yoshitsugu Miyazaki; Hiroshi Mukae; Shigeru Kohno
Journal:  Infect Immun       Date:  2016-06-23       Impact factor: 3.441

Review 4.  Roles of B Cell-Intrinsic TLR Signals in Systemic Lupus Erythematosus.

Authors:  Kongyang Ma; Jingyi Li; Yongfei Fang; Liwei Lu
Journal:  Int J Mol Sci       Date:  2015-06-09       Impact factor: 5.923

5.  COVID-19 diverse outcomes: Aggravated reinfection, type I interferons and antibodies.

Authors:  Rafael Cardoso Maciel Costa Silva; Christianne Bandeira-Melo; Heitor Afonso Paula Neto; André Macedo Vale; Leonardo Holanda Travassos
Journal:  Med Hypotheses       Date:  2022-09-09       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.